A Study of LY3473329 in Participants With Impaired and Normal Renal Function
Completed · Phase 1
Conditions studied: Renal Insufficiency
In brief
The main purpose of this study is to assess the amount of study drug (LY3473329) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to participants with normal renal function. The safety and tolerability of LY3473329 will also be evaluated in these participants. The study will last up to 8 weeks including screening period.
Key facts
- Study ID
- NCT05778864
- Run by
- Eli Lilly and Company
- People needed
- 47
- Starts
- 2023-03-17
- Expected to finish
- 2024-09-06
- Last updated by the study team
- 2024-10-28
Who can join
Age: 18 and older, up to 85. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Have a body mass index within the range 19.0 to 42.0 kilograms per meter squared (kg/m²)
- Men who agree to use highly effective or effective methods of contraception, women of childbearing potential (WOCP) who agree to use highly effective or effective methods of contraception, and women not of childbearing potential (WNOCBP) may participate in this trial
- Have clinical laboratory test results within the normal reference range for the population
You may not qualify if…
- Have a history or presence of an underlying disease, or surgical, physical, medical, or psychiatric condition that, in the opinion of the investigator, would potentially affect participant safety within the study
- Have any abnormality in the 12-lead electrocardiogram (ECG), blood pressure and/or pulse rate that, in the opinion of the investigator, increases the risks associated with participating in the study
- Hemoglobin less than 8 grams/deciliter (g/dL) and/or clinically significant anemia symptoms
- Have an average weekly alcohol intake that exceeds 21 units per week for males and 14 units per week for females or males older than 65 years of age
- Smoke more than 10 cigarettes per day or the equivalent
- Have donated blood of more than 500 milliliter (mL) within 3 months prior to screening
Where it is running
- Velocity Clinical Research, New Smyrna Beach — Edgewater, Florida, United States
- Advanced Pharma CR, LLC — Miami, Florida, United States
- Orlando Clinical Research Center — Orlando, Florida, United States
- Alliance for Multispecialty Research, LLC — Knoxville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.